RecruitingPhase 4NCT04604509

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

PISCES I: Precision Implemented Smoking Cessation Evaluation Study

Sponsor

M.D. Anderson Cancer Center

Enrollment

2,010 participants

Start Date

Aug 4, 2020

Study Type

INTERVENTIONAL

Conditions

Cigarette Smoking-Related Carcinoma

Summary

This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bupropion Hydrochloride Controlled-release, a drug called Nicotine Replacement, and others for people with cigarette smoking-related carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.